ModifiedUnitedHealthcarePolicy 2026T0640H

Minimally Invasive Spine Surgery Procedures

This UnitedHealthcare medical policy governs coverage and medical necessity determinations for a range of minimally invasive spinal procedures for Commercial and Individual Exchange plans, specifying which procedures are considered unproven/not medically necessary and providing definitions, background, and applicable billing codes. It affects providers submitting claims to UnitedHealthcare for these procedures.

Policy Summary

PayerUnitedHealthcare

PolicyMinimally Invasive Spine Surgery Procedures

Policy CodePolicy 2026T0640H

Change TypeDefinitions added/updated and supporting sections refreshed

Effective DateFeb 1, 2026

Next Review DateN/A

Key ActionObtain prior authorization when submitting requests for listed percutaneous lumbar procedures and include clinical indication, prior conservative therapy documentation, and supporting imaging or evidence.

SourceLink

POLICY UPDATE CHANGES

Added definition of 'Transforaminal Lumbar Interbody Fusion'.

Removed definition of Interlaminar Lumbar Instrumented Fusion (ILIF), Nucleoplasty, Percutaneous or Endoscopic Lumbar Fusion, Transforaminal (TESSYS ® ) and Interlaminar Endoscopic Surgical Systems, and Tubular Retractor.

Updated definitions for Automated Percutaneous Lumbar Discectomy (APLD), Axial Lumbar Interbody Fusion (AxiaLIF), Endoscope, Endoscopic Discectomy, Fluoroscopy, Image-Guided Minimally Invasive Lumbar Decompression (MILD ® ), Interbody Fusion, Laparoscopic Anterior Lumbar Interbody Fusion (LALIF), Open Spine Surgery, Percutaneous Endoscopic Lumbar Discectomy (PELD), Percutaneous Image-Guided Lumbar Decompression (PILD), Posterior Lumbar Spine Surgery, and Sacroplasty.

Updated Description of Services, Clinical Evidence, and References sections to reflect the most current information.

9procedures listed as unproven / not medically necessary

0200T, 0201T, 22586...

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria and Stance

inv-01: Not Medically Necessary / Unproven Procedures

The following spinal procedures are unproven and not medically necessary due to insufficient evidence of efficacy:

Unproven / Not Medically Necessary Procedures: Axial Lumbar Interbody Fusion (AxiaLIF) — presacral L5–S1 approach; Percutaneous Image‑Guided Lumbar Decompression (PILD); Percutaneous sacral augmentation (Sacroplasty), with or without balloon or bone cement; Automated Percutaneous Lumbar Discectomy (APLD); Percutaneous Endoscopic Lumbar Discectomy (PELD); Minimally Invasive Lumbar Decompression (MILD); Laparoscopic Anterior Lumbar Interbody Fusion (LALIF); Transforaminal Lumbar Interbody Fusion (TLIF) performed using only endoscopic visualization (percutaneous endoscopic TLIF).

Listed procedures considered unproven/not medically necessary due to insufficient evidence of efficacy.

Operational note: Listing of a procedure here indicates that available evidence does not demonstrate improved net health outcomes compared with standard surgical approaches; claims for these procedures may be at risk for denial as not medically necessary unless new, high‑quality comparative evidence is provided.

See policy Coverage Rationale and evidence summaries.

inv-02: Coverage stance by procedure

Coverage considerations based on current evidence summaries

AxiaLIF: Evidence is insufficient—no randomized controlled trials demonstrating improved net health outcomes compared with standard interbody fusion techniques; retrospective series report mixed radiographic and clinical outcomes and some higher rates of pseudarthrosis and revision, so AxiaLIF is considered investigational or restricted pending higher‑quality comparative data.

Supported by ECRI review, single‑center retrospective series, and postmarketing surveillance (see cited evidence).

LALIF / R‑ALIF: Available literature is largely older case series and nonrandomized studies; LALIF shows similar outcomes to mini‑open ALIF but with longer operative times and technical demands, and R‑ALIF evidence is preliminary—insufficient to support broad expansion of coverage without additional high‑quality studies.

Systematic review (Decker et al. 2025) found limited and heterogeneous data.

MILD / PILD: RCTs and observational studies report symptomatic improvement up to 1–2 years for ligamentum flavum hypertrophy, but long‑term durability and comparative effectiveness versus open decompression remain uncertain; coverage with specific criteria (documented indication, prior conservative therapy) may be appropriate.

Hayes and other systematic reviews note low‑quality evidence and need for longer‑term RCTs.

inv-03: Evidence-based coverage stance summaries

Coverage considerations based on available evidence summaries and technology assessments

Percutaneous image‑guided lumbar decompression (MILD/PILD): The body of evidence includes RCTs and cohort studies but is generally low quality with risk of bias; improvements in pain and function are observed up to 1–2 years, yet long‑term benefit and superiority to open decompression are unproven—coverage may be considered with defined patient selection and conservative therapy prerequisites.

Hayes and ECRI assessments found low‑quality evidence and uncertainty about long‑term outcomes.

Percutaneous laser disc decompression / PLDD: Evidence is limited and of low quality; some trials report noninferior short‑term outcomes but higher rates of subsequent surgery, yielding insufficient evidence to establish long‑term comparative effectiveness.

Brouwer RCT and HTA reports document higher reoperation rates and limited evidence quality.

Percutaneous endoscopic lumbar discectomy (PELD): Low‑to‑moderate quality evidence suggests similar short‑ and mid‑term outcomes to open discectomy with potential perioperative advantages (less blood loss, shorter stay), but heterogeneity and risk of bias limit definitive conclusions on comparative effectiveness and patient selection.

inv-04: Evidence‑based coverage considerations

Evidence synthesis findings relevant to coverage decisions (summary of comparative effectiveness):

Comparative outcomes summary: Systematic reviews and meta‑analyses indicate that endoscopic and percutaneous TLIF variants (PE‑TLIF, Endo‑LIF/Endo‑TLIF, BE‑LIF) and MIS‑TLIF have similar medium‑ to long‑term clinical outcomes, fusion rates, and complication/reoperation rates; endoscopic approaches often demonstrate lower blood loss, shorter hospital stay, and faster early recovery but may require longer operative or fluoroscopy time.

Findings summarized from Song 2022, Kou 2021, Zhu 2021, Zhao 2021, Kang 2021, and related meta‑analyses.

Limitations of the evidence: The literature is heterogeneous with numerous nonrandomized, retrospective, single‑center studies, small sample sizes, and limited follow‑up; high risk of bias and methodological defects are common, and authors consistently recommend well‑designed randomized trials with longer follow‑up to confirm comparative effectiveness and durability of benefit.

Consistent limitation across multiple systematic reviews and ECRI/HTA assessments.

The listing of a procedure or procedure code in this policy is for reference only and does not by itself indicate that the service is a covered benefit. Benefit coverage and any reimbursement or preauthorization requirements are determined by the member-specific benefit plan document and applicable law. The inclusion of a code in this policy does not guarantee payment or imply coverage.

Clinical society guidance and published guidelines inform exclusions and limitations in this policy. For example, fusion is not recommended for isolated lumbar stenosis without instability per AANS/CNS guidance, and NASS has reported insufficient evidence to recommend minimal-access fusion techniques over traditional open approaches for degenerative lumbar spondylolisthesis. Other specialty statements (ISASS, NASS) note limited evidence for certain interspinous/interlaminar devices and insufficient data to broadly recommend some minimally invasive devices without decompression; these guideline conclusions support restricting fusion and device coverage when indications are outside guideline-recommended uses.

Some devices and procedures lack sufficient high-quality comparative evidence to determine whether they improve net health outcomes compared with established surgical alternatives. Examples include novel biportal or dual-portal endoscopic fusion systems and other percutaneous endoscopic fusion techniques; systematic reviews and evidence assessments have concluded available studies are limited (case series, nonrandomized comparisons) and do not permit definitive conclusions about efficacy versus conventional fusion methods.

ECRI and related evidence reviews concluded that the evidence for some percutaneous transforaminal endoscopic discectomy systems is mixed and of low quality. The literature includes heterogeneous study designs, nonrandomized comparisons, and small single‑center series, resulting in uncertainty about comparative effectiveness and limiting definitive efficacy conclusions for these systems.

Definitions were added, revised, and removed in this policy update. Notably, the policy added a definition for Transforaminal Lumbar Interbody Fusion and removed definitions for several previously listed terms (e.g., Interlaminar Lumbar Instrumented Fusion, Nucleoplasty, Percutaneous or Endoscopic Lumbar Fusion, TESSYS® transforaminal systems, interlaminar endoscopic systems, and tubular retractor). These changes may affect how procedures are referenced in other sections and should be considered when interpreting coverage language and coding crosswalks.

Based on the evidence review, the following procedures are considered unproven and not medically necessary due to insufficient evidence of efficacy: Axial Lumbar Interbody Fusion (AxiaLIF); Percutaneous Image‑Guided Lumbar Decompression (PILD); Sacroplasty (with or without balloon or cement); Automated Percutaneous Lumbar Discectomy (APLD); Percutaneous Endoscopic Lumbar Discectomy (PELD); Minimally Invasive Lumbar Decompression (MILD); Laparoscopic Anterior Lumbar Interbody Fusion (LALIF); and TLIF performed using only endoscopic visualization.

Percutaneous image‑guided lumbar decompression techniques (MILD/PILD) and percutaneous laser disc decompression (PLDD) are supported by limited, low‑to‑moderate quality evidence. Systematic reviews and technology assessments report symptom improvements up to 1–2 years for some patients but note methodological limitations, unblinded trials, and uncertainty about long‑term durability and comparative effectiveness; overall, high‑quality evidence is insufficient to establish superiority over conservative care or open decompression.

Randomized controlled trials and other comparative studies that are unblinded, small, or otherwise at high risk of bias — or that report higher reoperation rates (for example, in some percutaneous laser disc decompression trials) — reduce confidence in net benefit. Where RCTs are unblinded or of low methodological quality, or where comparative data show increased rates of subsequent surgery without durable improvement, such interventions may be judged not medically necessary pending higher‑quality evidence.

When the body of evidence consists primarily of low‑quality, high‑risk‑of‑bias studies (nonrandomized, retrospective, single‑center case series) and lacks randomized controlled trials demonstrating clinically meaningful benefit, the procedure or device may be considered not medically necessary until higher‑quality evidence is available to establish an improvement in net health outcomes.

Procedure and Billing Codes

Applicable CPT / procedure codes (listed)CPT

0200T	Percutaneous sacral augmentation (sacroplasty), unilateral injection(s), including the use of a balloon or mechanical device, when used, 1 or more needles, includes imaging guidance and bone biopsy, when performed.
0201T	Percutaneous sacral augmentation (sacroplasty), bilateral injections, including the use of a balloon or mechanical device, when used, 2 or more needles, includes imaging guidance and bone biopsy, when performed.
22586	Arthrodesis, pre-sacral interbody technique, including disc space preparation, discectomy, with posterior instrumentation, with image guidance, includes bone graft when performed, L5-S1 interspace.
22630	Arthrodesis, posterior interbody technique, including laminectomy and/or discectomy to prepare interspace (other than for decompression), single interspace, lumbar.
22899	Unlisted procedure, spine.
62287	Decompression, percutaneous, of nucleus pulposus of intervertebral disc, any method utilizing needle-based technique to remove disc material under fluoroscopic imaging or other form of indirect visualization, with discography and/or epidural injection(s) at the treated level(s), when performed, single or multiple levels, lumbar.
62330	Decompression, percutaneous, with partial removal of the ligamentum flavum, including laminotomy for access, epidurography, and imaging guidance (i.e., CT or fluoroscopy), bilateral; one interspace, lumbar.
62331	Decompression, percutaneous, with partial removal of the ligamentum flavum, including laminotomy for access, epidurography, and imaging guidance (i.e., CT or fluoroscopy), bilateral; additional interspace(s), lumbar (List separately in addition to code for primary procedure).
62380	Endoscopic decompression of spinal cord, nerve root(s), including laminotomy, partial facetectomy, foraminotomy, discectomy and/or excision of herniated intervertebral disc, 1 interspace, lumbar.

Additional codesCPT / HCPCS

G0276

Blinded procedure for lumbar stenosis, percutaneous image-guided lumbar decompression (PILD) or placebo-control, performed in an approved coverage with evidence development (CED) clinical trial.

Codes referenced in textmixed

No codes listed

Minimum pain history required in some studies

Minimum required pain duration in some studies>= 3 months (minimum history of pain was mandatory in select retrospective and prospective series, e.g., Klessinger)

Context of requirementRequired as an inclusion criterion for PLDD series assessing resurgery and long‑term outcomes

Follow-up reportingMean follow‑up in PLDD cohorts reported ~35.6 months (Klessinger) with many patients followed >5 years

Prior Authorization, Documentation, and Billing Guidance

Prior Authorization

Coverage / Prior authorization reference

Verify member-specific benefits and prior authorization requirements before submitting any request. Coverage determinations for the procedures discussed in this policy are made based on the member's benefit plan and any applicable federal or state mandates; in the event of a conflict, the member-specific benefit plan governs.

Check the member-specific benefit plan for coverage determinations and any prior authorization requirements
Confirm applicable federal or state mandates that may affect coverage

Prior Authorization

Prior authorization recommended

Prior authorization is recommended for several minimally invasive and percutaneous lumbar procedures that have mixed, limited, or evolving evidence of comparative effectiveness. Obtaining prior authorization helps ensure the necessary clinical documentation is submitted for an individualized coverage review.

Prior authorization recommended for: AxiaLIF, LALIF/R-ALIF, MILD/PILD, and percutaneous laser disc decompression

Clinical Background and Rationale

Low back pain and radiculopathy from herniated discs are common conditions that frequently improve with conservative management. Surgical decompression is typically considered for persistent neuropathic symptoms after an adequate trial of conservative care. Minimally invasive and percutaneous techniques aim to reduce procedural morbidity, but many such approaches have limited high‑quality comparative evidence versus standard surgical decompression or fusion. This policy reflects those evidence limitations and specifies which minimally invasive procedures are considered unproven or not medically necessary.

Procedure and Device Definitions

Automated Percutaneous Lumbar Discectomy (APLD)

DefinitionAutomated Percutaneous Lumbar Discectomy (APLD): percutaneous removal of protruding disc material using a large‑bore needle inserted directly into the disc space (NASS, 2025).

ApproachPercutaneous, needle‑based into the disc space

Primary indicationTreatment of protruding/herniated lumbar disc material causing radiculopathy or back pain

Evidence/coverage stanceListed among procedures considered unproven / not medically necessary due to insufficient evidence of efficacy

Axial Lumbar Interbody Fusion (AxiaLIF)

DefinitionAxial Lumbar Interbody Fusion (AxiaLIF): presacral/trans‑axial (paracoccygeal) minimally invasive approach to L5–S1 interbody fusion accessing the spine along its long axis through a small incision next to the tailbone.

Policy Revision History

2026-02-01definition_changesLatest

Added definition of 'Transforaminal Lumbar Interbody Fusion' and revised/removed multiple other procedure and device definitions (e.g., removed ILIF, Nucleoplasty, certain endoscopic systems and tubular retractor definitions).

2026-02-01content_update

Updated Description of Services, Clinical Evidence, and References sections to reflect current information and refreshed supporting sections and citations.

Policy Summary

PayerUnitedHealthcare

PolicyMinimally Invasive Spine Surgery Procedures

Policy CodePolicy 2026T0640H

Change TypeDefinitions added/updated and supporting sections refreshed

Effective DateFeb 1, 2026

Next Review DateN/A

SourceLink

On This Page

Percutaneous/biportal endoscopic fusion (BE‑LIF, PE‑TLIF, dualPortal): Meta‑analyses and comparative series report similar fusion rates and medium‑term outcomes to MIS‑TLIF with advantages in blood loss and hospital stay for some endoscopic techniques; however, the evidence base is heterogeneous, often retrospective, and insufficiently powered to demonstrate superior net health outcomes—coverage decisions should consider the low quality and call for higher‑quality comparative trials.

Multiple systematic reviews (Song 2022, Kou 2021, Zhu 2021, Hu et al. 2025) summarize comparable outcomes and procedural tradeoffs.

Prior Authorization

Prior authorization recommended for percutaneous lumbar procedures

Percutaneous lumbar procedures often have low-to-insufficient or low-quality evidence regarding long-term comparative effectiveness. Prior authorization is recommended so that clinical indication, conservative therapy history, and supporting data can be reviewed before authorization is issued.

Prior authorization recommended for percutaneous image-guided lumbar decompression (PILD/MILD), percutaneous laser disc decompression, percutaneous sacroplasty, automated percutaneous lumbar discectomy, percutaneous endoscopic lumbar discectomy, and other percutaneous lumbar decompression procedures
Document prior conservative management and indication when requesting authorization

Documentation Required

Prior authorization: require clinical indication and supporting data

Prior authorization requests should include a clear clinical indication and sufficient supporting clinical data to allow medical necessity review. Examples of supporting documentation include relevant imaging, symptom duration and severity, objective neurologic findings, prior treatment responses, and operative plans when applicable.

Provide indication (diagnosis) and rationale for the procedure versus alternatives
Include imaging reports, physical examination findings, and symptom duration
Attach prior treatment records (see conservative therapy documentation callout)

Denial Risk

Denials possible for unproven procedures

Claims for procedures designated in this policy as unproven or not medically necessary may be denied. Prior authorization does not guarantee coverage; medical necessity is determined by clinical review and the member-specific benefit plan.

Procedures listed as unproven/not medically necessary (e.g., AxiaLIF, PILD/Percutaneous laser disc decompression, MILD/PILD in certain indications) may be denied as not medically necessary
Listing of codes in the policy is for reference and does not imply coverage

Denial Risk

Evidence insufficiency triggers denial risk

Insufficiency or low quality of evidence noted in the literature may lead to denial of coverage if submitted documentation does not demonstrate a clear benefit over standard treatment. High risk-of-bias studies and lack of comparative RCT data are particular concerns.

Insufficient comparative evidence for AxiaLIF, PILD versus open decompression, percutaneous laser disc decompression, and other percutaneous procedures may trigger denial risk
Low-quality studies, small sample sizes, retrospective designs, or lack of control groups increase denial risk

Denial Risk

MILD/PILD evidence insufficiency

For MILD/PILD procedures, the literature includes mixed-quality evidence and uncertainty about long-term durability and comparative effectiveness. Authorization and coverage requests should address these evidence limitations explicitly.

MILD/PILD evidence limitations versus placebo or open decompression may place coverage requests at risk
Submit robust documentation of symptoms, imaging confirming hypertrophied ligamentum flavum when applicable, and prior conservative therapy

Denial Risk

Low quality evidence may trigger denial risk

Low-quality evidence, including studies with high risk of bias, inconsistent inclusion/exclusion criteria, or substantial heterogeneity, may lead to noncoverage unless strong, patient-specific justification and comparative data are provided.

High risk-of-bias case series or retrospective studies without comparative outcomes are insufficient for routine coverage
Provide higher-quality comparative data or strong clinical rationale for individual cases

Documentation Required

AxiaLIF documentation needs

When requesting coverage or authorization for AxiaLIF, include documentation that compares expected outcomes and risks with standard fusion techniques (e.g., ALIF, TLIF/MIS-TLIF). The published literature lacks RCTs demonstrating AxiaLIF's comparative safety and effectiveness, so comparative clinical and radiographic data are particularly important.

Include comparative evidence vs standard fusion techniques when submitting AxiaLIF requests
Provide radiographic outcomes, complication/reoperation rates, and rationale why AxiaLIF is chosen for this member

Step Therapy

Conservative care expectation

Conservative management is generally the initial approach for many causes of low back pain and radiculopathy. Prior authorization reviewers expect documentation of prior conservative care attempts and their duration before considering coverage for many minimally invasive or surgical procedures.

Document nonoperative management such as physical therapy, medications, activity modification, and epidural steroid injections when applicable
State duration and response to conservative treatments

Step Therapy

Conservative therapy prerequisite (MILD/PILD)

For procedures such as MILD/PILD, require documentation that appropriate conservative therapies were attempted and failed prior to the procedure. The literature and some guideline recommendations indicate conservative therapy was an inclusion criterion in many trials.

Document the types of conservative therapies tried (e.g., physical therapy, medications, injections), duration, and objective lack of sufficient improvement
If conservative therapy was contraindicated or not feasible, provide clinical justification

Step Therapy

Conservative management prior to percutaneous procedures

Because long-term benefit and comparative effectiveness of many percutaneous lumbar procedures remain uncertain, reviewers generally expect a stepwise management approach with documentation that conservative management failed before proceeding to percutaneous interventions.

Document failed conservative management prior to percutaneous procedures such as percutaneous laser disc decompression, PLDD, and others
Include objective measures of ongoing neurologic compromise or functional limitation when present

Documentation Required

Conservative therapy documentation

Maintain comprehensive documentation of prior conservative therapy and its outcomes when submitting prior authorization or coverage requests. Adequate documentation supports clinical necessity determinations and helps mitigate denial risk stemming from insufficient evidence.

Include dates, modalities, duration, and clinician notes describing response to conservative therapy
Attach imaging reports, neurologic exam findings, and any specialist evaluations

AxiaLIF — presacral/transaxial minimally invasive approach for L5–S1; evidence limited

Definition / approachAxiaLIF (presacral/transaxial): a minimally invasive presacral approach for L5–S1 interbody fusion entered via a small incision adjacent to the tailbone to access the disc along the spine's long axis.

Evidence summaryNo RCTs demonstrating safety and efficacy versus standard fusion; case series and registry data at high risk of bias—evidence insufficient to conclude comparative clinical benefit.

Policy implicationConsidered investigational/unproven in this policy and associated with denial risk when submitted without robust comparative evidence.

Laparoscopic Anterior Lumbar Interbody Fusion and Robotic-assisted ALIF (LALIF / R-ALIF)

DefinitionLaparoscopic Anterior Lumbar Interbody Fusion (LALIF) and Robotic‑assisted ALIF (R‑ALIF): minimally invasive anterior approaches using laparoscopy or robotic systems to perform ALIF.

Evidence summarySystematic review (48 studies) found LALIF outcomes similar to mini‑open ALIF but with longer operative times, higher technical demands, and potentially higher complication rates; LALIF is now rarely used. R‑ALIF data limited and preliminary; further high‑quality studies needed.

Operational considerationsR‑ALIF may reduce certain complications but has increased training, logistical, and cost barriers limiting broader adoption.

Minimally Invasive Lumbar Decompression / PILD / MILD

DefinitionMinimally Invasive Lumbar Decompression / MILD (also PILD): image‑guided posterior decompression targeting hypertrophied ligamentum flavum to enlarge the canal and relieve neurogenic claudication.

Clinical outcomesRandomized and nonrandomized trials report symptomatic improvement lasting up to 1–2 years with low adverse event rates (e.g., adverse event rate ~8.2% in pooled trials), but heterogeneity and short follow‑up limit conclusions.

Long‑term durabilityLong‑term effectiveness and direct comparative benefit versus open decompression remain uncertain; evidence rated low to moderate quality and additional RCTs are needed.

PLDD / Dekompressor / percutaneous laser disc decompression

DefinitionPLDD / Dekompressor / percutaneous laser disc decompression: umbrella term for percutaneous devices/techniques that remove or ablate disc material (e.g., Dekompressor device, laser systems).

Study evidenceMixed results: some cohort studies report short‑term pain relief but retrospective series show high resurgery/rescue surgery rates (e.g., PLDD resurgery 26% in Klessinger).

Policy implicationProcedures and devices in this group lack consistent high‑quality comparative evidence and are considered investigational or unproven for routine coverage.

Sacroplasty — percutaneous cement augmentation for sacral insufficiency fractures

DefinitionSacroplasty: percutaneous cement augmentation (PMMA) of sacral insufficiency fractures to reduce pain and improve mobility; performed via multiple approaches, with or without balloon assistance.

Outcomes evidenceSystematic review/meta‑analysis reported high technical (98.9%) and clinical (95.7%) success with sustained VAS reduction up to 12 months, but studies are primarily case series without RCTs.

Coverage considerationEvidence supports safety/effectiveness for osteoporotic or malignant SIFs but remains low quality; broader indications lack sufficient evidence.

BE-LIF / PE-TLIF / dualPortal — biportal or percutaneous endoscopic fusion approaches

DefinitionBE‑LIF / PE‑TLIF / dualPortal: biportal or percutaneous endoscopic approaches to lumbar interbody fusion intended to reduce invasiveness compared with open or conventional MIS‑TLIF.

Comparative evidenceMeta‑analyses and systematic reviews report some benefits (less blood loss, shorter hospital stay, faster early recovery) but are limited by retrospective designs and small samples; fusion and complication rates often similar to MIS‑TLIF.

Evidence gapStrong RCT evidence comparing these techniques with standard approaches is lacking; long‑term outcomes need further study.

Endo‑TLIF / Endo‑LIF / PE‑TLIF

DefinitionEndo‑TLIF / Endo‑LIF / PE‑TLIF: percutaneous or full‑endoscopic transforaminal lumbar interbody fusion techniques using endoscopic visualization and percutaneous instrumentation to perform TLIF.

Clinical findingsMeta‑analyses and comparative series report similar medium‑term clinical outcomes and fusion rates vs MIS‑TLIF, with advantages in blood loss and hospital stay but often longer operative/fluoroscopic times.

Evidence limitationsAvailable studies are heterogeneous and frequently nonrandomized; additional well‑designed trials are needed to confirm comparative effectiveness and safety.

Transforaminal Lumbar Interbody Fusion and related updated definitions

UpdateTransforaminal Lumbar Interbody Fusion definition was added; related definitions were revised or removed in the 02/01/2026 policy update.

ImplicationSeveral prior device/procedure definitions (e.g., ILIF, Nucleoplasty, certain endoscopic systems) were removed or updated; check updated definitions for coding/coverage interpretation.

Evidence notePercutaneous/ endoscopic TLIF variants have limited high‑quality RCT evidence; meta‑analyses suggest similar short‑term outcomes to MIS‑TLIF but heterogeneity limits firm conclusions.